ST-168

Overview

ST-168 is an orally active MEK/PI3K inhibitor with an IC 50 of 182 nM against MEK1 and IC 50 values ​​of 69.2, 41.7, 1482 and 2293 nM against PI3Kα , PI3Kδ , PI3Kβ and PI3Kγ respectively. ST-168 completely inhibits the phosphorylation of ERK1/2 and AKT and induces cancer cell death in a 3D tumor sphere model. ST-168 demonstrates significant antitumor effects in the A375 melanoma mouse model. ST-168 improves the ocular toxicity profile of MEK inhibitors, showing lower caspase activation levels, indicating reduced apoptosis induction. ST-168 can be used in melanoma research.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MEK | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Caspase

Product Information

• Catalog No.: HY-120281
• CAS No.: 2126038-25-1
• Molecular Formula: C41H44F5IN10O7
• Molecular Weight: 1010.75
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source